CAPTRUST Financial Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.11M | Buy |
16,490
+5,513
| +50% | +$688K | ﹤0.01% | 1193 |
|
|
2025
Q4 | $1.34M | Buy |
10,977
+2,170
| +25% | +$249K | ﹤0.01% | 1321 |
|
|
2025
Q3 | $882K | Buy |
8,807
+555
| +7% | +$50K | ﹤0.01% | 1501 |
|
|
2025
Q2 | $684K | Sell |
8,252
-2,475
| -23% | -$197K | ﹤0.01% | 1545 |
|
|
2025
Q1 | $870K | Sell |
10,727
-13,208
| -55% | -$1.18M | ﹤0.01% | 1356 |
|
|
2024
Q4 | $2.16M | Buy |
23,935
+5,683
| +31% | +$551K | 0.01% | 855 |
|
|
2024
Q3 | $1.8M | Buy |
18,252
+10,501
| +135% | +$1.03M | 0.01% | 899 |
|
|
2024
Q2 | $719K | Sell |
7,751
-2,273
| -23% | -$204K | ﹤0.01% | 1327 |
|
|
2024
Q1 | $951K | Buy |
10,024
+1,003
| +11% | +$93.1K | ﹤0.01% | 1149 |
|
|
2023
Q4 | $805K | Sell |
9,021
-5
| -0.1% | -$371 | ﹤0.01% | 1403 |
|
|
2023
Q3 | $659K | Sell |
9,026
-105
| -1% | -$8.39K | ﹤0.01% | 1462 |
|
|
2023
Q2 | $760K | Sell |
9,131
-2,501
| -22% | -$209K | ﹤0.01% | 1376 |
|
|
2023
Q1 | $886K | Sell |
11,632
-978
| -8% | -$81.1K | ﹤0.01% | 1100 |
|
|
2022
Q4 | $1.05M | Buy |
12,610
+1,420
| +13% | +$115K | 0.01% | 946 |
|
|
2022
Q3 | $888K | Sell |
11,190
-3,068
| -22% | -$259K | 0.01% | 978 |
|
|
2022
Q2 | $1.06M | Buy |
14,258
+3,281
| +30% | +$246K | 0.01% | 810 |
|
|
2022
Q1 | $987K | Buy |
10,977
+41
| +0.4% | +$3.79K | 0.01% | 858 |
|
|
2021
Q4 | $1.22M | Buy |
10,936
+1,121
| +11% | +$135K | 0.01% | 730 |
|
|
2021
Q3 | $1.23M | Sell |
9,815
-831
| -8% | -$107K | 0.01% | 666 |
|
|
2021
Q2 | $1.44M | Buy |
10,646
+2,324
| +28% | +$306K | 0.01% | 600 |
|
|
2021
Q1 | $1.13M | Buy |
8,322
+804
| +11% | +$120K | 0.01% | 657 |
|
|
2020
Q4 | $1.06M | Sell |
7,518
-110
| -1% | -$14.1K | 0.01% | 595 |
|
|
2020
Q3 | $861K | Sell |
7,628
-21
| -0.3% | -$2.35K | 0.01% | 553 |
|
|
2020
Q2 | $860K | Buy |
7,649
+1,345
| +21% | +$132K | 0.01% | 549 |
|
|
2020
Q1 | $462K | Sell |
6,304
-876
| -12% | -$77.6K | 0.01% | 605 |
|
|
2019
Q4 | $680K | Buy |
7,180
+1,099
| +18% | +$95.1K | 0.01% | 600 |
|
|
2019
Q3 | $464K | Buy |
6,081
+2,217
| +57% | +$184K | 0.02% | 416 |
|
|
2019
Q2 | $339K | Buy |
3,864
+968
| +33% | +$82.6K | 0.01% | 456 |
|
|
2019
Q1 | $262K | Buy |
2,896
+943
| +48% | +$80.2K | 0.01% | 468 |
|
|
2018
Q4 | $140K | Sell |
1,953
-11,101
| -85% | -$894K | 0.01% | 509 |
|
|
2018
Q3 | $1.25M | Buy |
13,054
+185
| +1% | +$17.9K | 0.06% | 198 |
|
|
2018
Q2 | $1.23M | Buy |
12,869
+11,760
| +1,060% | +$1.08M | 0.07% | 162 |
|
|
2018
Q1 | $93K | Buy |
1,109
+67
| +6% | +$6.12K | 0.01% | 467 |
|
|
2017
Q4 | $88K | Sell |
1,042
-20
| -2% | -$1.68K | 0.01% | 471 |
|
|
2017
Q3 | $95K | Buy |
1,062
+535
| +102% | +$42.9K | 0.01% | 251 |
|
|
2017
Q2 | $41K | Buy |
+527
| New | +$37.4K | 0.01% | 174 |
|
|
2016
Q4 | – | Sell |
-240
| Closed | -$13K | – | 203 |
|
|
2016
Q3 | $13K | Buy |
+240
| New | +$14.8K | ﹤0.01% | 84 |
|
|
2016
Q2 | – | Sell |
-240
| Closed | -$12K | – | 215 |
|
|
2016
Q1 | $12K | Hold |
240
| – | – | ﹤0.01% | 175 |
|
|
2015
Q4 | $17K | Buy |
+240
| New | +$16.4K | ﹤0.01% | 163 |
|
Other funds holding XBI
CAPTRUST Financial Advisors's XBI Position: Q1 2026 in Review
CAPTRUST Financial Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 50% in Q1 2026, buying an estimated $688K and bringing the position to 16,490 shares worth $2.11M. The position accounts for ﹤0.01% of the portfolio, ranked #1193.
CAPTRUST Financial Advisors first reported a position in XBI in Q4 2015 and has held it in 39 quarters since. The position peaked at $2.16M in Q4 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- CAPTRUST Financial Advisors held 16,490 shares of State Street SPDR S&P Biotech ETF worth $2.11M as of Q1 2026.
- CAPTRUST Financial Advisors bought 5,513 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $688K.
- State Street SPDR S&P Biotech ETF made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #1193 holding.
- CAPTRUST Financial Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2015 and has held it in 39 quarters since.
- CAPTRUST Financial Advisors's State Street SPDR S&P Biotech ETF position peaked at $2.16M in Q4 2024.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.